X4 has entered an exclusive agreement with taiba rare for distributing and commercialising Xolremdi in select Middle Eastern ...
“We look forward to working together to further expand the global reach of Xolremdi for people with WHIM syndrome.” Xolremdi is a selective CXC chemokine receptor 4 (CXCR4) antagonist and ...
X4 Pharmaceuticals announced the validation of its Marketing Authorization Application (MAA) for mavorixafor, a treatment for WHIM syndrome, by the European Medicines Agency (EMA). This rare ...
X4 Pharmaceuticals (XFOR) and taiba rare, a taiba Healthcare company with specialty & orphan drug marketing, sales, and distribution ...
The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI ®, an oral, once-daily ...
Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome granted in 2024 Decision on MAA expected in 1H 2026 BOSTON ...
X4 Pharmaceuticals, a company driven to improve the lives of people with rare diseases of the immune system, announced that its Marketing Authorization Application (MAA) for mavorixafor for the ...
The EMA previously granted orphan designation to mavorixafor in WHIM syndrome. In April 2024, mavorixafor received U.S. Food and Drug Administration approval as XOLREMDI ®, an oral, once-daily ...
The headcount reduction will save money that the company will use in developing mavorixafor, its CXCR4 antagonist that last year received FDA approval to treat WHIM syndrome, in the larger patient ...